Neusoft IntelliRay Secures Over RMB 100 Million Series C Funding to Advance High-Quality, Precision Radiotherapy

Recently, Shenyang Dongruan Zhirui Radiotherapy Technology Co., Ltd. (hereinafter referred to as "Dongruan Zhirui") announced the completion of its Series C financing round, exceeding RMB 100 million, jointly led by Le Li Capital and Neusoft Capital. It is reported that the funds from this round will be utilized for the research and development of high-end radiotherapy equipment and information systems, market expansion, and the construction of new industrial bases, thereby leading the precise and high-quality development of China's radiotherapy industry.

Established in 2018, Dongruan Zhirui is a national high-tech enterprise dedicated to the development of high-end medical electron linear accelerators and comprehensive informatics systems for tumor radiotherapy covering the entire workflow. The company also promotes the application of technologies such as artificial intelligence and cloud computing in the field of radiotherapy. Targeting critical areas in China’s radiotherapy sector that urgently require breakthroughs—including complete system integration, core technologies, and key components—Dongruan Zhirui has conducted focused technological research and achieved a series of innovative breakthroughs. It has taken the lead in undertaking key national R&D programs during both the 13th and 14th Five-Year Plan periods. Notably, the company’s latest flagship product, the “NeuRT Aurora Smart Radiotherapy Platform,” has received approval for market launch from the National Medical Products Administration (NMPA). This product marks an innovative breakthrough in domestically produced high-end medical electron linear accelerators. Built on the design philosophy of extreme precision, maximum efficiency, and intelligent reliability, and equipped with the world’s first Spiral Volumetric Modulated Arc Therapy (SVMAT) technology, it offers a superior option for tumor radiotherapy.

In recent years, the Chinese government has intensified its efforts to promote the localization of medical equipment, with radiotherapy becoming a key focus of national industrial policy, thereby providing ample room for development for domestic radiotherapy enterprises. With the implementation of policies such as the "14th Five-Year Plan" for the allocation of large-scale medical equipment and the new round of large-scale equipment renewal initiatives, China’s radiotherapy industry is undergoing unprecedented transformation, driven by sustained national encouragement of domestic substitution and support for independent research, development, and innovation. Shenyang Dongruan Zhirui Radiotherapy Technology Co., Ltd. is actively building a “Precision Radiotherapy Smart Ecosystem” underpinned by full-stack product digitalization and intelligence. By innovatively developing the independently owned “NeuRT Aurora Intelligent Radiotherapy Platform,” the “NeuOIS Polaris Oncology Information System” covering the entire diagnosis and treatment workflow, and the “NeuOIS Cloud Remote Radiotherapy Platform” based on cloud computing power, Shenyang Dongruan Zhirui comprehensively assists medical institutions at all levels in establishing unprecedented digitally intelligent oncology radiotherapy centers.

Yu Xiaopeng, CEO of Dongruan Zhirui, stated: Empowering Quality with Intelligence, Dongruan Zhirui will shoulder the critical mission of domestic substitution for large-scale radiotherapy equipment. By leveraging technological innovation to cultivate new quality productive forces in precision radiotherapy, and fostering a thriving ecosystem through industry-medical integration and win-win partnerships, we will jointly build a new future for China’s radiotherapy industry.

Yue Dongxiao of Leli Capital believes: With the high incidence of cancer in China, the widespread adoption of radiotherapy equipment is imminent, and national policy support is bringing new opportunities to the radiotherapy market. Centering on precise tumor radiotherapy technologies, products, and solutions, Shenyang Dongruan Zhirui Radiotherapy Technology Co., Ltd. has established significant advantages in the precision, efficiency, patient treatment experience, and innovative therapeutic research of tumor radiotherapy, making it a company with high growth potential and investment value in the field of radiotherapy technology. We look forward to working together with Zhirui to jointly promote the development of radiotherapy technology.

Sun Zhen, General Manager of Neusoft Capital, statedIn recent years, the medical device industry has undergone significant transformation. Neusoft Zhirui’s independently developed innovative products have not only substantially improved treatment efficiency and patient experience for oncology patients but also laid a solid foundation for future clinical exploration through their exceptional performance. As a long-standing shareholder of Zhirui, Neusoft Capital is honored to have participated in the company’s latest round of financing alongside external investors, marking a major milestone in its development. We look forward to Zhirui achieving further success and making even greater contributions to China’s oncology treatment landscape.

It is reported that Dongruan Zhirui previously completed RMB 100 million in Series A financing in 2020 and RMB 250 million in Series B financing in 2021. Following this round of funding, Dongruan Zhirui will accelerate efforts to promote precision, intelligence, and accessibility in the radiotherapy industry in China and globally.